Cerebrospinal Fluid Diagnostics of Alzheimer's Disease in Patients with Idiopathic Normal Pressure Hydrocephalus.

"CONFLICT OF INTEREST HZ has served on scientific advisory boards or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures at symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Heikki Lukkarinen and Henrik Zetterberg are Editorial Board Members of this journal but were not involved in the peer-review process nor had access to any information regarding its peer-review. The other authors report no conflicts of interest."

"FUNDING The study was funded by Kuopio University Hospital VTR fund (Grant number: 5252614), Academy of Finland (#339767, 338182), Sigrid Juselius Foundation (no specified grant number), the Strategic Neuroscience Funding of the University of Eastern Finland, the Finnish Cultural Foundation, North Savo Regional Fund (#65221674), Alzheimer’s Association AD Strategic Fund (#ADSF-21-831386-C), Maire Taponen Foundation, and The Finnish Medical Foundation. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), and the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C)."